<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002346</url>
  </required_header>
  <id_info>
    <org_study_id>232B</org_study_id>
    <secondary_id>GS-93-402</secondary_id>
    <nct_id>NCT00002346</nct_id>
  </id_info>
  <brief_title>The Safety and Effectiveness of Bis-POM PMEA in HIV-Infected Patients</brief_title>
  <official_title>A Phase I/II Study of Safety, Tolerance, Pharmacokinetics, and Anti-HIV Activity of 9-[2-(Bispivaloyloxymethyl)Phosphonylmethoxyethyl]Adenine (Bis-POM PMEA) and Placebo in HIV-Infected Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NIH AIDS Clinical Trials Information Service</source>
  <brief_summary>
    <textblock>
      To study the safety, tolerance, single and multiple dose pharmacokinetics, and anti-HIV&#xD;
      activity of bis-POM PMEA ( adefovir dipivoxil ) versus placebo when administered orally on a&#xD;
      daily basis for 2 weeks to HIV-infected patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients are randomized to receive bis-POM PMEA at one of three fixed dose levels or placebo&#xD;
      daily for 2 weeks. At each dose level, nine patients receive bis-POM PMEA and three patients&#xD;
      receive placebo.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <enrollment>36</enrollment>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adefovir dipivoxil</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Allowed:&#xD;
&#xD;
          -  Prophylaxis with aerosolized pentamidine, fluconazole, ketoconazole,&#xD;
             trimethoprim/sulfamethoxazole, or dapsone, provided a stable regimen has been&#xD;
             maintained for at least 4 weeks prior to study entry.&#xD;
&#xD;
        Patients must have:&#xD;
&#xD;
          -  HIV seropositivity.&#xD;
&#xD;
          -  CD4 count &gt;= 100 cells/mm3.&#xD;
&#xD;
          -  p24 antigen (immune-complex dissociated) &gt;= 50 pg/ml.&#xD;
&#xD;
          -  Life expectancy of at least 6 months.&#xD;
&#xD;
        Prior Medication:&#xD;
&#xD;
        Allowed:&#xD;
&#xD;
          -  Prior prophylaxis with aerosolized pentamidine, fluconazole, ketoconazole,&#xD;
             trimethoprim/sulfamethoxazole, or dapsone.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        Co-existing Condition:&#xD;
&#xD;
        Patients with the following symptoms or conditions are excluded:&#xD;
&#xD;
          -  Active, serious infection (other than HIV infection) requiring parenteral antibiotic&#xD;
             therapy.&#xD;
&#xD;
          -  Malignancy other than cutaneous Kaposi's sarcoma.&#xD;
&#xD;
          -  Clinically significant cardiac disease, including symptoms of ischemia, congestive&#xD;
             heart failure, or arrhythmia.&#xD;
&#xD;
          -  Gastrointestinal malabsorption syndrome.&#xD;
&#xD;
          -  Inability to take oral medication.&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Any parenteral antibiotic therapy.&#xD;
&#xD;
          -  Diuretics.&#xD;
&#xD;
          -  Amphotericin B.&#xD;
&#xD;
          -  Didanosine (ddI).&#xD;
&#xD;
          -  Fluconazole.&#xD;
&#xD;
          -  Foscarnet.&#xD;
&#xD;
          -  Ganciclovir.&#xD;
&#xD;
          -  Interferon-alpha.&#xD;
&#xD;
          -  Interferon-beta.&#xD;
&#xD;
          -  Isoniazid.&#xD;
&#xD;
          -  Aminoglycoside antibiotics.&#xD;
&#xD;
          -  Ketoconazole (topical allowed).&#xD;
&#xD;
          -  Itraconazole.&#xD;
&#xD;
          -  Rifabutin.&#xD;
&#xD;
          -  Rifampin.&#xD;
&#xD;
          -  Stavudine (d4T).&#xD;
&#xD;
          -  Zalcitabine (ddC).&#xD;
&#xD;
          -  Zidovudine (AZT).&#xD;
&#xD;
          -  Lamivudine (3TC).&#xD;
&#xD;
          -  Any investigational agents (except with sponsor approval).&#xD;
&#xD;
          -  Systemic therapy for Kaposi's sarcoma.&#xD;
&#xD;
        Patients with the following prior condition are excluded:&#xD;
&#xD;
        History of lactose intolerance.&#xD;
&#xD;
        Prior Medication:&#xD;
&#xD;
        Excluded within 2 weeks prior to study entry:&#xD;
&#xD;
          -  Any parenteral antibiotic therapy.&#xD;
&#xD;
          -  Diuretics.&#xD;
&#xD;
          -  Amphotericin B.&#xD;
&#xD;
          -  Didanosine (ddI).&#xD;
&#xD;
          -  Fluconazole.&#xD;
&#xD;
          -  Foscarnet.&#xD;
&#xD;
          -  Ganciclovir.&#xD;
&#xD;
          -  Interferon-alpha.&#xD;
&#xD;
          -  Interferon-beta.&#xD;
&#xD;
          -  Isoniazid.&#xD;
&#xD;
          -  Aminoglycoside antibiotics.&#xD;
&#xD;
          -  Ketoconazole (topical allowed).&#xD;
&#xD;
          -  Itraconazole.&#xD;
&#xD;
          -  Rifabutin.&#xD;
&#xD;
          -  Rifampin.&#xD;
&#xD;
          -  Stavudine (d4T).&#xD;
&#xD;
          -  Zalcitabine (ddC).&#xD;
&#xD;
          -  Zidovudine (AZT).&#xD;
&#xD;
          -  Lamivudine (3TC).&#xD;
&#xD;
          -  Any investigational agents (except with sponsor approval).&#xD;
&#xD;
        Excluded within 4 weeks prior to study entry:&#xD;
&#xD;
        Systemic therapy for Kaposi's sarcoma. Active substance abuse (including alcohol) as&#xD;
        determined by questionnaire or positive drug screen.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Johns Hopkins Univ</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>James JS. GS 840 (adefovir dipivoxil): broad-spectrum antiviral trial, CD4 count under 100. AIDS Treat News. 1997 Feb 7;(No 264):4-5.</citation>
    <PMID>11364103</PMID>
  </reference>
  <verification_date>March 1995</verification_date>
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>June 23, 2005</last_update_submitted>
  <last_update_submitted_qc>June 23, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2005</last_update_posted>
  <keyword>Acquired Immunodeficiency Syndrome</keyword>
  <keyword>AIDS-Related Complex</keyword>
  <keyword>Antiviral Agents</keyword>
  <keyword>Adenine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adefovir</mesh_term>
    <mesh_term>Adefovir dipivoxil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

